By Sheeba M. | April 25, 2026
Institutional Capital Floods Cannabis as Rescheduling Pressure Mounts
The cannabis industry is at an inflection point. With Biden administration officials signaling serious consideration of deschedule petitions and three major bills in Congress pushing for federal legalization, institutional investors are no longer sitting on the sidelines.
BlackRock, Fidelity, and Vanguard have all increased their passive cannabis holdings in the last 90 days, according to SEC filings. This marks a shift from the 2024 bear market when institutions were net sellers.
The Rescheduling Timeline
The DEA’s scientific review of cannabis, launched in 2022, was supposed to conclude in 2024. The revised timeline suggests a recommendation by Q3 2026. Here’s what matters to investors:
- Schedule III reclassification would allow pharmaceutical research and bank access for MSOs
- Full deschedule would remove federal interstate commerce barriers
- Tax code 280E repeal would immediately boost MSO profitability by 20-30%
The larger cultivators like Curaleaf have 400+ retail locations and $1.3B in revenue. A deschedule event would unlock immediate bank financing for expansion, interstate M&A, and premium valuations.
Which Plays Are Moving?
Trulieve continues to show strength in the SE region with positive cash flow. Green Thumb has the most exposure to East Coast legalization momentum. Smaller MSOs like Acreage and Ayr are also positioning for institutional flows.
The playbook is clear: rescheduling + institutional capital = rerating. The question isn’t if, but when.
Sources
- SEC EDGAR Filings — BlackRock, Vanguard cannabis holdings
- DEA Cannabis Rescheduling Review — Official timeline and process
- U.S. Congress Bills — Proposed federal legalization legislation
Track cannabis stocks with the Weedstock Real-Time Tracker